![](https://bloximages.newyork1.vip.townnews.com/wfmz.com/content/tncms/assets/v3/editorial/1/28/1281f771-d9bc-56f3-ade9-7ae9abbc898f/66b161ffa0fc4.image.jpg?crop=1763%2C926%2C0%2C124&resize=1200%2C630&order=crop%2Cresize)
Phase 2 Clinical Trial Clarifies Role of JAK2 Inhibitor in Combating Acute Graft-Versus-Host Disease
The results of a phase 2 trial led by Roswell Park's Dr. Brian Betts answer a longstanding question in stem cell transplantation. While adding the JAK inhibitor pacritinib to the treatment regimen for patients undergoing stem cell transplant did not …